


TRIC-TB: A fast-moving bilateral collaboration

Global AMR R&D Hub – 2 December 2020



The History: A perfect PPP developing a new medicine against TB




In June 2019, TRIC-TB was awarded funding of € 6.92 million from the EU IMI2 & EFPIA

TRIC-TB: The consortium



Consortium Leader
Beneficiary receiving funding




Consortium Partner
Beneficiary not receiving funding

The project team is the core operational unit of TRIC-TB

Advantages of the TRIC-TB consortium

- ✓ TRIC-TB is a focused consortium of one SME, BioVersys and one big Pharma, GSK
- ✓ TRIC-TB combines an agile, fast moving SME with the experience and capabilities of a big industry partner
- ✓ All necessary expertise from end of pre-clinical to clinical development (microbiology, efficacy and DMPK, toxicology, CMC, drug development and clinical trials, regulatory etc.) is covered within the TRIC-TB consortium
- ✓ No unnecessary delays due to out of focus topics and unnecessary IP dilutions as it sometimes happens with bigger consortia

TRIC-TB: next steps



Milestone: BVL-GSK098 ready for First in Human (FIH) studies in H2 2020

- BVL-GSK098 has received approval for FIH study and started recruitment.
- The Phase 2a / EBA (Early Bactericidal Activity) study in patients will be run in collaboration with TASK in South Africa (2021) and has been accepted to receive funding from the European Developing Countries Trial Partnership (EDCTP).

Acknowledgements.



Alain Baulard

Thomas Maitre
Nicolas Veziris

David Barros
Robert Bates
Gary Boyle
Matt Davies
Maria Davy
Andy Fowler
Emma Francis
Stephanie Gresham
Modesto Remuinan
Georgios Vlasakakis
Richard Ward
Alison Webster
Deborah Wong

Stefano Biondi
Marilyne Bourotte
Jonathan Butcher
Glenn Dale
Rosangela Frita
Marc Gitzinger
Sergio Lociuero
Thorsten Meyer
Michel Pieren
Andrej Trauner



Dr Marc Gitzinger, PhD

Chief Executive Officer

marc.gitzinger@bioversys.com

Dr Jonathan J. Butcher, PhD

Head of BD and Alliance Management

jonathan.j.butcher@bioversys.com

Dr Michel Pieren, PhD

Project Manager

michel.pieren@bioversys.com

Dr Modesto Remuiñán Blanco

Project Leader

modesto.b.remuinan@gsk.com